Carboplatin plus paclitaxel in combination with bevacizumab for the treatment of adenocarcinoma with interstitial lung diseases

Suzuki, Hidekazu; Hirashima, Tomonori; Kobayashi, Masashi; Okamoto, Norio; Matsuura, Yuka; Tamiya, Motohiro; Morishita, Naoko; Okafuji, Kohei; Shiroyama, Takayuki; Morimura, Osamu; Morita, Satomu; Kawase, Ichiro

doi:10.3892/mco.2013.82

Cited by 9 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rate of grade 1–5 IRP in different treatment regimens was compared among four groups including chemotherapy, ICIs monotherapy, dual ICIs combination and ICIs+chemotherapy. Given that bevacizumab has little impact on the occurrence of IRP, 34 35 only one study (IMpower-150) in the ICIs+chemotherapy group added bevacizumab to both the experimental and control arm was included in the NMA. Furthermore, we subdivided the four treatment groups into seven subgroups based on the different types of ICIs: chemotherapy, PD-1 monotherapy, PD-L1 monotherapy, PD-1/PD-L1+cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), PD-1+chemotherapy, PD-L1+chemotherapy, CTLA-4+chemotherapy.…”

Section: Resultsmentioning

confidence: 99%

Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis

Chen

Zhang

Hou

et al. 2020

J Immunother Cancer

View full text Add to dashboard Cite

BackgroundImmune checkpoint inhibitors (ICIs) have dramatically revolutionized lung cancer treatment, providing unprecedented clinical benefits. However, immune-related pneumonitis (IRP) caused by ICIs has aroused widespread concern due to its high rate of discontinuation and mortality. This network meta-analysis (NMA) aims to compare the risks of IRP among different regimens for advanced lung cancer.MethodsPhase II and III randomized clinical trials (RCTs) were searched from electronic databases. The rates of grade 1–5 IRP and grade 3–5 IRP were systematically extracted. An NMA was conducted among chemotherapy, ICIs monotherapy, dual ICIs combination, and ICIs+chemotherapy. Subgroup analysis was also compared based on specific types of ICIs.ResultsTwenty-five RCTs involving 17,310 patients were eligible for inclusion. Compared with chemotherapy, ICI-based regimens were associated with an increased risk of grade 1–5 IRP and grade 3–5 IRP. Compared with ICIs+chemotherapy, ICIs monotherapy (grade 1–5: OR 2.14, 95% credible interval 1.12 to 4.80; grade 3–5: 3.03, 1.491 to 6.69) and dual ICIs combination (grade 1–5: 3.86, 1.69 to 9.89; grade 3–5: 5.12, 2.01 to 13.68) were associated with a higher risk of grade 1–5 IRP and grade 3–5 IRP. No significant difference was found between dual ICIs combination and ICIs monotherapy in grade 1–5 IRP (1.85, 0.91 to 3.37) or in grade 3–5 IRP (1.65, 0.81 to 3.37). Besides, compared with programmed cell death protein 1 (PD-1) inhibitors (2.56, 1.12 to 6.60), a lower risk of grade 1–5 IRP was observed in programmed cell death ligand 1 (PD-L1) inhibitors.ConclusionCompared with chemotherapy, using ICIs is associated with an increased risk of IRP. ICIs+chemotherapy is associated with a lower risk of IRP compared with dual ICIs combination and ICIs monotherapy. PD-1 inhibitors are associated with a higher risk of 1–5 grade IRP compared with PD-L1 inhibitors.

show abstract

Section: Resultsmentioning

confidence: 99%

Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis

Chen

Zhang

Hou

et al. 2020

J Immunother Cancer

View full text Add to dashboard Cite

show abstract

“…Considering the prevalence of AE-ILD in patients with idiopathic pulmonary fibrosis or idiopathic nonspecific interstitial pneumonia even without lung cancer (8.5% or 4.2% in a 1-year period, respectively) ( 12 , 13 ), the incidence of AE-ILD by chemotherapy with sb-PC regimen might be within the permissible range. Furthermore, recent reports have revealed an addition of bevacizumab to sb-PC might provide an effective and safe treatment option for patients with advanced non-squamous NSCLC and ILD ( 14 - 16 ). However, the optimum chemotherapy regimen for advanced lung SCC with preexisting ILD has not been determined.…”

Section: Introductionmentioning

confidence: 99%

The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias

et al. 2018

View full text Add to dashboard Cite

Objective Although lung squamous cell carcinoma (SCC) accounts for 20-30% of lung cancer cases, new treatment options are limited. The CA031 study showed that nanoparticle albumin-bound-paclitaxel (nab-PTX) plus carboplatin produced a significantly higher overall response rate (41%) than solvent-based paclitaxel plus carboplatin in patients with lung SCC. However, the safety and efficacy of combination chemotherapy of nab-PTX and carboplatin has not yet been established for patients with concurrent lung SCC and idiopathic interstitial pneumonias (IIPs). The aim of this study was to assess the safety and efficacy profiles of nab-PTX and carboplatin in patients with lung SCC and concurrent IIPs. Methods Eight patients with inoperable-stage lung SCC and IIPs were treated with nab-PTX plus carboplatin in a first-line setting between June 2013 and December 2016. One of the eight was a woman, and the median age was 77 (range=72-80) years. Their clinical outcomes, including chemotherapy-associated acute exacerbation of IIPs, were retrospectively investigated. Results The overall response rate was 50%, the median progression-free survival time was 5.6 months, and the median overall survival time was 8.1 months. No patients experienced chemotherapy-related exacerbation of IIPs in the first-line treatment with nab-PTX plus carboplatin. However, IIPs worsened in two of four patients who received second-line chemotherapy. Conclusion Combination chemotherapy of nab-PTX and carboplatin may be an effective and safe treatment option for patients with inoperable lung SCC with IIPs. To confirm this, a large-scale prospective study is needed.

show abstract

“…There are two studies examining the safety and efficacy of CP‐BEV with additional BEV monotherapy in patients with interstitial lung disease (ILD). In one study, no patients developed CIP . In the second study, one patient developed CIP, out of 10 patients with the combination of advanced NSCLC and ILD .…”

Section: Discussionmentioning

confidence: 94%

Bevacizumab‐induced chronic interstitial pneumonia during maintenance therapy in non‐small cell lung cancer

Sekimoto

Kato

Shukuya

et al. 2016

Respirology Case Reports

View full text Add to dashboard Cite

Bevacizumab is a monoclonal antibody targeting the vascular endothelial growth factor receptor and a key drug for advanced non‐small cell lung cancer. There are few reports describing bevacizumab‐induced chronic interstitial pneumonia.A 62‐year‐old man with advanced non‐small cell lung cancer was admitted to our hospital with dyspnea. He previously received four courses of carboplatin plus paclitaxel with bevacizumab combination therapy and thereafter received four courses of maintenance bevacizumab monotherapy. A chest‐computed tomography scan on admission revealed diffuse ground glass opacity. He had not received any other drugs and did not have pneumonia. Thus, he was diagnosed with bevacizumab‐induced chronic interstitial pneumonia and was treated with a high dose of corticosteroids. After steroid treatment, his dyspnea and radiological findings improved.This case report is the first description of bevacizumab‐induced chronic interstitial pneumonia during maintenance therapy in a patient with non‐small cell lung cancer.

show abstract

Carboplatin plus paclitaxel in combination with bevacizumab for the treatment of adenocarcinoma with interstitial lung diseases

Cited by 9 publications

References 9 publications

Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis

Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis

The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias

Bevacizumab‐induced chronic interstitial pneumonia during maintenance therapy in non‐small cell lung cancer

Contact Info

Product

Resources

About